Non-small cell lung cancer stage II

11 clinical trials

Quick filters

Clinical trials for Non-small cell lung cancer stage II

11 trials across Europe

See all trials →

Quick filters

11 Clinical trials

Non-small cell lung cancer stage III+1

Recruiting

Registered drugNo placebo

Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years
Substances:Carboplatin
Sponsor:Innate Pharma

Contact Research Centre

Non-small cell lung cancer stage IIIA+2

Recruiting

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Non-small cell lung cancer+4

Recruiting

Registered drugNo placebo

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Non-small cell lung cancer stage III+3

Recruiting

Registered drugNo placebo

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer+5

Not recruiting

Registered drugNo placebo

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Zimberelimab
Sponsor:AIO-Studien gGmbH

Contact Research Centre

See all trials →

Non-small cell lung cancer stage II

Clinical trials for Non-small cell lung cancer stage II

Non-small cell lung cancer stage III+1

Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

Non-small cell lung cancer stage IIIA+2

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Non-small cell lung cancer+5

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Non-small cell lung cancer+4

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Non-small cell lung cancer stage III+3

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Non-small cell lung cancer+5

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.